Application of pantohematogen dry for treatment of discirculatory disorders in chronic prostatitis (experimental and clinical study)

Abstract

PURPOSE: To study in experiment and in clinical conditions the effectiveness of the preparation pantogematogen dry, obtained from the blood of a maral, for the correction of dyscirculatory disorders in the prostate gland.

MATERIALS AND METHODS: The experimental and morphological part of the work was performed on 90 male Wistar rats with local venous congestion in the small pelvis due to ligation of the internal iliac veins. Animals of the main group (n = 30) underwent enteral correction with dry pantohematogen (in a daily dose of 10 mg per 100 g of animal weight) starting from the 7^th day after modeling the disease, the course was 14 days. The rats of the 2nd group (n = 30) after modeling of venous stasis were not treated. Group 3 consisted of intact animals. During the clinical phase of the study, 61 patients with chronic congestive prostatitis were treated. All patients received standard therapy, and patients in the treatment group (n = 30) additionally received highly dispersed aerosol transrectal irrigation with an aqueous solution of pantohematogen, daily, for a course of 10 procedures.

RESULTS AND DISCUSSION: Morphological examination of the prostate gland of laboratory animals with experimental discirculatory prostatitis and its subsequent enteral correction with panthematogen dry indicated significant differences compared with animals of the 2^nd group. A tendency towards restoration of the normal structure of the prostate, its metabolism, regional and organ blood and lymph outflow, improvement of the drainage-detoxification and transport activity of its regional lymph nodes was noted. In the clinical part of the study, the effectiveness of the use of pantogematogen in patients with chronic congestive prostatitis was shown. At the end of the course of treatment in patients of the 1^st group, the disappearance of pain (in 72.4% of cases) and dysuric (in 86.2% of cases) syndromes was observed, and in the rest – a decrease in their intensity. According to the TRUS of the prostate in patients of the 1^st group, after treatment in 52% of cases, a decrease in the volume of the prostate was noted.

CONCLUSIONS: The results of an experimental clinical study indicate the prospects for the inclusion of pantogematogen in the complex therapy of patients with chronic congestive prostatitis.

Keywords

dry pantohematogen / venous congestion in the small pelvis / experimental model / discirculatory prostatitis / chronic congestive prostatitis

References

[1] Bozhedomov VA. Modern opportunities for the treatment of chronic prostatitis. Andrology and Genital Surgery. 2016;17(3):10–22. (In Russ.) DOI: 10.17650/2070-9781-2016-17-3-10-22

[2] Божедомов В.А. Современные возможности лечения хронического простатита // Андрология и генитальная хирургия. 2016. Т. 17, № 3. С. 10–22. DOI: 10.17650/2070-9781-2016-17-3-10-22

[3] Molochkov VA, Il’in II. Hronicheskij uretrogennyj prostatit. Moscow: Medicina; 2010. 304 p. (In Russ.)

[4] Молочков В.А., Ильин И.И. Хронический уретрогенный простатит. М.: Медицина, 2010. 304 с.

[5] Kubanova AA, Vavilov AM, Volnuhin VA, et al. Racional’naya farmakoterapiya zabolevanij kozhi i infekcij, peredavaemyh polovym putem / Ed. by A.A. Kubanova. Moscow: Litterra, 2007; 512 (In Russ.)

[6] Кубанова А.А., Вавилов А.М., Волнухин В.А., и др. Рациональная фармакотерапия заболеваний кожи и инфекций, передаваемых половым путем / под общей ред. А.А. Кубановой. М.: Литтерра, 2007. 512 с.

[7] Paulis G. Inflammatory mechanisms and oxidative stress in prostatitis: the possible role of antioxidant therapy. Res Rep Urol. 2018;17(10):75–87. DOI: 10.1007/978-3-319-71282-6_4

[8] Paulis G. Inflammatory mechanisms and oxidative stress in prostatitis: the possible role of antioxidant therapy // Res Rep Urol. 2018. Vol. 17, No. 10. P. 75–87. DOI: 10.1007/978-3-319-71282-6_4

[9] Dendeberov ES, Logvinov LA, Vinogradov IV, et al. Taktika vybora skhemy terapii bakterial’nogo prostatita. Russian Medical Journal. 2011;19(32): 2071–2074. (In Russ.)

[10] Дендеберов Е.С., Логвинов Л.А., Виноградов И.В., и др. Тактика выбора схемы терапии бактериального простатита // Русский медицинский журнал. 2011. Т. 19, № 32. С. 2071–2074.

[11] Kulchenko NG, Yatsenko EV. Phytotherapy for inflammatory diseases of the prostate. Research and Practical Medicine Journal. 2019;6(3):87–97. DOI: 10.17709/2409-2231-2019-6-3-8

[12] Кульченко Н.Г., Яценко Е.В. Фитотерапия при воспалительных заболеваниях предстательной железы // Исследования и практика в медицине. 2019. Т. 6, № 3. С. 87–97. DOI: 10.17709/2409-2231-2019-6-3-8

[13] Vermassen T, Van Praet C, Poelaert F, et al. Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis. Biochem Med (Zagreb). 2015;25(3):439–449. DOI: 10.11613/BM.2015.045

[14] Vermassen T., Van Praet C., Poelaert F., et al. Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis // Biochem Med (Zagreb). 2015. Vol. 25, No. 3. P. 439–449. DOI: 10.11613/BM.2015.045

[15] Suskind AM, Berry SH, Ewing BA, et al. The prevalence and overlap of interstititial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology Male Study. J Urol. 2013;189(1):141–145. DOI: 10.1016/j.juro.2012.08.088

[16] Suskind A.M., Berry S.H., Ewing B.A., et al. The prevalence and overlap of interstititial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology Male Study // J Urol. 2013. Vol. 189, No. 1. P. 141–145. DOI: 10.1016/j.juro.2012.08.088

[17] Pushkar DYu, Rasner PI, Kotenko DV, et al. Specific features of lower urinary tract symptoms in men living in the moscow region. Results of the epidemiological study. Urology. 2018;(3):20–23. (In Russ.) DOI: 10.18565/urology.2018.3.20-28

[18] Пушкарь Д.Ю., Раснер П.И., Котенко Д.В., и др. Особенности симптомов нижних мочевыводящих путей у мужчин Московского региона. Результаты эпидемиологического исследования // Урология. 2018. № 3. С. 20–28.

[19] Shpienya ES. Klassifikaciya UPOINT: osobennosti i preimushchestva. Vestnik Rossijskogo obshchestva urologov. 2019;(2):10. (In Russ.)

[20] Шпиленя Е.С. Классификация UPOINT: особенности и преимущества // Вестник Российского общества урологов. 2019. № 2. С. 10.

[21] Segal AS. Diagnostika i lechenie hronicheskogo prostatita. Russian Medical Journal. 2003;11(8):453–458 (In Russ.)

[22] Сегал А.С. Диагностика и лечение хронического простатита // Русский медицинский журнал. 2003. Т. 11. № 8. С. 453–458.

[23] Kozlov BI, Popova IS. Pantolechenie. Posobie dlya vrachej i farmacevtov. Barnaul; 2014. 44 p. (In Russ.)

[24] Козлов Б.И., Попова И.С. Пантолечение. Пособие для врачей и фармацевтов. Барнаул, 2014. 44 с.

[25] Lazareva VA. Primenenie pantogematogena v kompleksnom lechenii bol’nyh hronicheskim prostatitom. Metodicheskoe posobie dlya vrachej. Novosibirsk; 2007. (In Russ.)

[26] Лазарева В.А. Применение пантогематогена в комплексном лечении больных хроническим простатитом. Методическое пособие для врачей. Новосибирск, 2007.

[27] Tihonov IV. Effektivnost’ ispol’zovaniya biologicheski aktivnoj dobavki k pishche “Fitopan M” v kompleksnoj sanatornoj reabilitacii bol’nyh hronicheskim prostatitom. Aktual’nye problem vosstanovitel’noj mediciny, kurortologii I fizioterapii: Sbornik nauchnyh trudov Vserossijskogo foruma “Zdravnica”. Saint Petersburg, 2004; P. 245. (In Russ.)

[28] Тихонов И.В. Эффективность использования биологически активной добавки к пище «Фитопан М» в комплексной санаторной реабилитации больных хроническим простатитом // Актуальные проблемы восстановительной медицины, курортологии и физиотерапии: Сборник научных трудов Всероссийского форума «Здравница». СПб, 2004 С. 245.

[29] Tihonov IV. Regional’nye limfaticheskie uzly predstatel’noj zhelezy v norme, pri venoznom zastoe v malom tazu i v usloviyah fizio- i fitokorrekcii: [dissertation] Novosibirsk; 2008. (In Russ.) Available from: http://medical-diss.com/medicina/regionarnye-limfaticheskie-uzly-prostaty-v-norme-pri-venoznom-zastoe-v-malom-tazu-i-v-usloviyah-fizio-i-fitokorrektsii.

[30] Тихонов И.В. Региональные лимфатические узлы предстательной железы в норме, при венозном застое в малом тазу и в условиях физио- и фитокоррекции: автореф. дис. … д-ра мед. наук. Новосибирск, 2008. Режим доступа: http://medical-diss.com/medicina/regionarnye-limfaticheskie-uzly-prostaty-v-norme-pri-venoznom-zastoe-v-malom-tazu-i-v-usloviyah-fizio-i-fitokorrektsii Дата обращения: 08.04.21.

[31] Avcyn AP, ZHavoronkov AA, Rish MA, Strochkova LS. Mikroelementozy cheloveka. Moscow: Medicina; 1991. 496 p. (In Russ.)

[32] Авцын А.П., Жаворонков А.А., Риш М.А., Строчкова Л.С. Микроэлементозы человека. М.: Медицина, 1991. 496 с.

[33] Borodin YuI, Konenkov VI, Poveshchenko AF, editors. Problemy limfangiologii. Novosibirsk: Manuskript; 2010. 403 p. (In Russ.)

[34] Проблемы лимфангиологии / под ред. Ю.И. Бородина, В.И. Коненкова, А.Ф. Повещенко. Новосибирск: Манускрипт, 2010. 403 с.

RIGHTS & PERMISSIONS

Eco-Vector